Writing
I write about life sciences commercialization from the operator's seat. AI is how the work is changing.
Get new posts in your inbox.
Practitioner-level. No trend-watching.
What I write about
Click a topic to switchAcross 19 first-time launchers, the gap between naming a commercial owner and FDA approval ran from 12 months to 98. There is no convention, only a sequence.
Most commercial teams have stopped arguing about whether AI belongs inside the work. That fight is over. Nobody I talk
AI Inside Commercial OperationsFor a connected device, the customer, the data, and the trust are commercial decisions. Make them before clearance, or they get made for you.
Pharma measures every molecule against a control. Almost no AI gets the same. Six systems here do.
Launch PlaybookMost teams running multi-market launch think the hard problem is localization. It is not. The hard part is orchestration: building an operating model eleven markets can actually run while still producing one brand. Six elements make it work, and most teams only build two.
AI Inside Commercial OperationsMost pharma teams are using AI. Fewer have made it part of how their commercial operation actually runs. That distinction is structural, not philosophical. Here is what it looked like when I built it at Novartis.
I'll email you when I publish.
Not on a schedule. Only when I have something worth reading.